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Abstract 
Stunting remains a major nutritional problem worldwide, especially in middle and low-
income countries including Indonesia. A number of nutrition feeding programs to cure 
stunting is basically addressing the problem of malnutrition. These programs are particularly 
designed to promote recovery of normal metabolic function and weight gain. The currently 
available remedial formula for malnutrition contains energy and nutrients to recover their 
weight, but there is less nutrition that would support optimal functional development of 
tissues including central nervous system. Research has well documented that sufficient 
intakes of dietary omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) are 
important for optimal health throughout the lifespan, especially on brain development and 
cognition. We review evidence for the role of food sources of these fatty acids on children’s 
health and growth. There is very little work done on remedial formula enriched with n-3 
LCPUFA for malnutrition and optimal health, highlighting a need for intervention studies 
investigating the health benefits of the formula for malnutrition and optimal health, which 
may prevent stunting but also may promote optimal health.  
Keywords: stunting, health benefits, omega-3 long chain polyunsaturated fatty acid 
1. Introduction
Stunting defined as height-for-age Z-score <-2.0 according to WHO growth standards remains 
a major nutritional problem worldwide, especially in middle-income and low-income 
countries including Indonesia. Stunting occurs in one-third of children under 5 yo and it 
causes 14% of childhood death in developing countries
1
. According to the Indonesian national
basic health research data
2
, the national prevalence of stunting in Indonesia was 37.2% which
was divided into 18% of stunting (<-2.0 z-score ≥-3.0) and 19.2% of severe stunting (z-score 
<-3.0). This number increased from the previous national survey in 2010 and 2007, which 
were 35.6% and 36.8%, respectively. Following the survey, an annually nutritional status 
monitoring has been conducted under the coordination of the Ministry of Health of Indonesia 
and found that in 2015 prevalence of stunting in children under 5 yo was 29%
3
, which slightly
decreased in 2016 of 27.5%
4
, but increased in 2017 of 29.5%
5
. More importantly, the
prevalence of stunting is not decreasing. 
A number of nutrition feeding programs to treat stunting is basically addressing the 
problem of malnutrition such as using biofortification, prebiotic foods and remedial formula 
such as ready to use therapeutic foods (RUTF) that meet WHO standard and formula known 
as F75 and F100 as well as modification dried skim cotton oil (Modisco). The last two 
formulas are more familiar in treatment of malnutrition in Indonesia. RUTF are energy dense, 
micronutrient enhanced pastes with a homogenous mix of lipid rich foods that can be directly 
given to patient without cooking. The nutritional profile of the RUTF is similar to the WHO-
recommended therapeutic milk formula used for inpatient therapeutic feeding programmes. 
Currently, the availability of RUTF is supported by the UNICEF as a part of community-
based management for acute-malnourished children globally
6
. The F-75 is designed to
promote recovery of normal metabolic function and nutrition electrolytic balance, hence it is 
initially admitted to in-patients with no adequate appetite and/or have a major medical 
complication. In this stage rapid weight gain is precarious, hence patients do not gain weight 
during this stage. Once the acute condition is stabilized, it is advised to change the diet to F-
100 which enables to recover weight and lean body tissue loss
7
.
Malnutrition children do not only need diets containing energy and nutrients to 
recover their weight, but also nutrients that support optimal functional development of tissues 
including central nervous system. A study by Danaei et al. (2016) concluded that the leading 
risk worldwide for stunting is fetal growth restriction being defined as term and small of 
gestational age – 10.8 million cases of stunting out of 44.1 million
8
. Hence sufficient dietary
intake of n-3 LCPUFA are essential to support normal brain development, especially in the 
critical period including during pregnancy, lactation as well childhood.  
The n-3 LCPUFA are involved in various neuronal processes, ranging from regulation 
of gene transcription to effects on cellular signalling processes
9
, and protection against the
pathogenesis of retinal diseases
10
. Nutrient deficiency during the brain growth spurt, which is




In the RUTF as well as F75/100 and Modisco that are being used to date, the n-3 
LCPUFA composition is limited (Supplemental Table 1, 2 and 3). In general, intervention 
studies used the F75/F100 as well as Modisco and RUTF showed an improvement of weight 
but limited data were reported on height.  The efficacy of RUTF has been evaluated in a 







, and concluded that RUTF significantly improved weight gain of the children. A
study in Indonesia using quasy experimental pre-posttest with control group design in 
outpatient malnourished children aged 6-59 months showed that 5 weeks intervention with 
F75/F100 increase weight of the children of 507 g compared to control group which only 
gained 80 g weight
15
. Another study using randomized blinded pre-posttest with control group
design of inpatients malnourished children aged 1-3 yo reported that after 6 months 
intervention, the weight gain of children in the intervention group who received Modisco with 
elemental milk formula which contains medium chain triglyceride and polymer carbohydrate 
is significantly higher (1527 g) than in control group given Modisco with regular milk 
formula (726 g)
16
. Moreover, the data showed that the improvement of weight for height in
the intervention group is significantly higher (z-score from -3.59 to -1.57) than in control 
group (z-score from -3.99 to -2.98)
16
.
The effect of long chain PUFA substitution for malnutrition children have been reported 
in 2 studies by Jones et al. (2015)
17
 and Hsieh et al. (2015)
18
. In study by Jones et al. (2015)
reported that malnourished children who had received high-oleic RUTF made with peanut oil 
from a high-oleic acid peanut cultivar, hence the ratio of linoleic acid (LA) to alpha-linolenic 
acid (ALA) achieving 1:1 had a significantly better weight-for height (WFH) at the time they 
recovered from malnutrition compared to children who were fed with standard RUFT that 
contained 53 times more LA than ALA, although still marginally below average weight-for-
height
17
. The levels of n-3 eicosapentaenoic acid (n-3 EPA) and n-6 DPA decreased from 3.2 
to 2.4%
1717
. This indicates that the standard RUTF did not support circulating DHA levels. In 
contrast, the children with high-oleic RUTF showed increased EPA and DPA and protected 
the decreasing of DHA levels during recovery period. In addition, compared to children 
receiving RUTF, high-oleic RUTF also induced a lowering of arachidonic acid (AA) levels, 
indicating that less LA was transformed to AA or that AA was displaced from plasma 
phospholipids by the increased levels of n-3 LCPUFA
17
. Another study by Hsieh et al. (2015) 
showed that DHA levels in red blood cells membranes significantly decreased after 4 weeks 
intervention by standard RUTF (from 5.2% to ~4%)
18
. “In the children receiving fish oil, 
DHA levels in RBC membranes increased over time to a level around 6-8%. Only 
supplementation with fish oil increased EPA levels, while flax oil-RUTF did not change the 
overall n-6 to n-3 ratio compared to baseline. This ratio increased with standard RUTF but 
decreased with the fish oil supplementation to flax oil RUTF
18
. In this paper, we review the 
potential benefits of n-3 LCPUFA for optimizing growth and development of stunted 
children. 
In this paper we review 1) n-3 LCPUFA metabolism to highlight the importance of n-
3 LCPUFA and not rely on the conversion of ALA to n-3 LCPUFA; 2) the health benefits of 
n-3 LCPUFA (and not ALA) during pregnancy, lactation and throughout offspring growth 
and development; 3) the recommended intakes and compare those to actual intakes to 
highlight the importance that we need to increase our intakes of n-3 LCPUFA; 4) how we can 
meet these recommended intakes through various n-3 LCPUFA enriched foods and 5) the 
rationale for the inclusion of n-3 LCPUFA in RUTF which may prevent stunting.   
 
2. n-3 LCPUFA metabolism 
Plants are able to synthesise LA (18:2n-6) and ALA (C18:3n-3) but human beings cannot 
synthesise LA and ALA and they need to obtain these polyunsaturated fatty acids (PUFA) 
from their diet and therefore they are considered essential fatty acids
19
. The metabolism of 
these essential PUFA to the long chain PUFA (LCPUFA) including arachidonic acid (AA, 
20:4n-6) in the n-6 pathway and eicosapentaenoic acid (EPA, 20:5n-3), docosapentaenoic acid 
(DPA, 22:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) from the n-3 pathway, has been 
well described
20,21
 and shown in figure 1. Delta-6 desaturase is the enzyme in the first step of 
the pathway for both the n-6 and n-3 pathways. Furthermore, delta-6 desaturase is the enzyme 
that converts tetracosapentaenoic acid (24:5n-3) to tetrahexaenoic acid (24:6n-3), which is 
then converted to docosahexaenoic acid (DHA, 22:6n-3) via beta-oxidation. Studies have 
shown that this latter step involving delta-6 desaturase is limited due to the competition of the 
other fatty acid substrates for the enzyme and hence de novo DHA synthesis is 
limited
22,23,24,25,26,27
. Therefore DHA may be considered as an essential nutrient
28
, or at least a 
semi-essential nutrient, that is a nutrient that can be synthesised but not in the quantity 
required for optimal health. 
People who consume a vegan or vegetarian diet generally do not consume meat, fish 
and seafood, so they do not consume preformed n-3 LCPUFA including DHA. Therefore, 
they need to rely on their ability to metabolise ALA to EPA, DPA and DHA. One study 
showed that the mean serum levels of EPA and DHA expressed as percent of total fatty acids 
are much lower in vegans 0.63% and 0.85% respectively compared to non-vegetarians with 
EPA and DHA levels of 2.33% and 2.25% respectively in Finnish men and women aged 24-
52 years
29
. This is further evidence that consumption of preformed n-3 LCPUFA is better than 
relying on the conversion of ALA to the n-3 LCPUFA. 
Supplementation with 9g LA and 2.8g ALA during pregnancy compared to 10.9g LA as 
the control, resulted in an approximate 2 fold increase in maternal plasma ALA levels, but 
there were no increases in maternal EPA, DPA and DHA
30
. This supplementation resulted in 
a 2 fold increase in neonatal plasma EPA levels, but no increased levels of neonatal plasma 
DPA and DHA
30
. This study demonstrates that supplementation with the precursor of DHA, 
namely ALA, does not result in increased DHA in the maternal and the fetal circulation. 
However, supplementation with preformed DHA (600mg per day from 20 weeks gestation 
until delivery) resulted in increased maternal and cord blood DHA levels
31
, suggesting that 
consumption of preformed DHA during pregnancy is superior to consuming ALA and then 
converting ALA to DHA. 
In a study of children aged 0-18 years with disorders of amino acid metabolism who 
consume protein-restricted diets (and hence do not consume pre-formed n-3 LCPUFA e.g. 
fish or seafood, egg and meat products), their erythrocyte DHA concentrations were 30% 
lower compared to healthy children, whilst concentrations of arachidonic acid (AA) did not 
differ between the groups
25
.This evidence suggests that these children do not have a problem 
with the elongation and desaturation enzymes because LA is converted to AA. However, due 
to high dietary LA levels, the ability to convert ALA to DHA is reduced
25
. In another cross-
sectional study of children with allergies, who eliminated food groups such as milk, egg, fish 
and vegetables, those children had approximately two-fold lower levels of plasma EPA and 
DHA compared to healthy children, whilst the plasma concentrations of AA and ALA did not 
differ
32
. These studies suggest that pre-formed n-3 LCPUFA needs to be consumed to fulfil 
physiological requirements, and that conversion of ALA to n-3 LCPUFA is not adequate for 
optimal health. Furthermore, evidence from our ancient diet, epidemiology, DHA status 
regulation and randomised controlled trials supports that DHA is essential
28
, that is, we must 
consume DHA in our diets. 
 
 
Figure 1: Metabolism of n-3 LCPUFA and eicosanoids, adopted from: Ratnayake & Galli, 
2009
20
; SanGiovanni & Chew 2005
21
 with some modifications 
 
3. Health benefits of n-3 LCPUFA  
3.1 The role of n-3 LCPUFA on neurological development  
DHA is a crucial element in the nervous system, which is responsible for development of the 




. It is the most fluidizing compound in cell membrane
35
, which is 
fundamental for growing membranes
36
.. The need for DHA in very early pregnancy has been 
shown in a prospective, observational study of human pregnancy where there was a rapid 
early increase in the maternal rate of change of plasma DHA concentration from 0.1 to 1.6 
nmol DHA per millilitre of plasma per day by 29 days post luteinising hormone surge that 
coincided with the closure of the neural tube
37
. This increased plasma DHA concentration was 
2 fold higher in twin pregnancies than in singleton pregnancies, emphasizing the metabolic 
response to increased demand for DHA at the critical time of the closure of the neural tube
37
. 
The metabolic response was increased synthesis of DHA from ALA, as delta-6 desaturase 
correlated with the rate of change of DHA plasma concentration between 18 and 29 days post-
LH surge (R
2
adj = 0.41, P=0.0002)
37
. 
The retina, functionally an extension of the brain, is highly enriched in DHA, especially 
in retinal photoreceptor outer segment disc membranes
38
. DHA is highly accumulated in the 
brain and retinal photoreceptor cells, forming 10-20 % and >60% of total fatty acid 
composition in the brain and retina, respectively
39,40
. During the third trimester of gestation 




3.1.1 DHA from birth to old age 
Concentration of DHA in plasma phospholipids and red blood cells rapidly falls by ~50% 
within 4 months after birth without an exogenous source of DHA, but is maintained by 
consumption of human breast milk or DHA-fortified formula feeding
43
). The accretion of 
DHA in the brain continues up to 2 years of age and progressively rises in the cerebral cortex 
until 18 years of age
44,45
 and even life-long
33
. A study has compared brain tissue obtained 
from individuals ranging from fetal age to 82 years to assess percentages of AA and DHA 
methyl esters in cerebral cortex ethanolamine glycerophospholipids
46
. Concentrations of AA 
and DHA in the one month old human infant were roughly equal or 1:1 (16.5% AA and 
16.1% DHA) but by the 82
nd 
year the percentage of DHA had more than doubled and 




3.2 Maternal plasma DHA and LA during pregnancy and offspring growth, weight and 
adiposity  
Increased consumption of n-3 LCPUFA in the maternal diet and increased levels of n-3 
LCPUFA in the umbilical cord plasma phospholipids has been associated with lower 
adiposity in children age 3 years; where the lower adiposity has been shown by lower skinfold 
thickness, odds of obesity and concentration of leptin, a biomarker of adiposity
47
. Increased 
fish intake is also associated with lower adiposity but the relationship is weaker than n-3 
LCPUFA
47
. The increased n-6 to n-3 ratio in the maternal diet, maternal blood and cord blood 
is also associated with increased adiposity at 3 years of age, but this is due to reduced n-3 
rather than increased n-6
47
. 
In a cohort longitudinal study DHA was positively associated with height from birth to 
age 5 years, in that for a 5% level increase, height was 0.63 (0.09, 1.16) cm and 1.29 (0.34, 
2.24) cm higher at 1 and 5 years respectively
48
. There were no associations between DHA and 
weight, BMI and head circumference
48
. In this same study, LA was associated with all 
measures of fetal growth at 26 and 32 weeks gestation and at birth with exception of birth 
length and abdominal circumference. LA was not associated with overall post-natal growth as 
associations faded after one month after birth. LA was increased with fat mass as measured by 
skinfold thickness and neonatal abdominal adipose tissue volume (measured by MRI) which 
showed increases in superficial subcutaneous and internal tissues
48
. These results demonstrate 
that DHA is associated with growth in terms of increased height but not weight (or fatness), 
whilst plasma LA status during pregnancy is associated with fetal growth, neonatal body size 




3.3 DHA and cognition throughout the lifespan 
DHA is important throughout the lifespan, from neurological development and cognition 
through infancy, childhood, adolescents, adulthood and the elderly which has been reviewed 
by Stonehouse 2014
49
 and Weiser et al. 2016
50
. Briefly, people with low habitual intake of n-
3 LCPUFA, children who are malnourished and with low literacy ability and older people 
with mild cognitive decline may benefit the most from consuming DHA
49
. DHA can 
influence many signalling pathways, enzyme activities, receptor systems, membrane 
structures and dynamics that results in optimal neurological development, maintenance of the 
nervous system and slows cognitive decline through aging and thereby having optimal 




3.3.1 DHA supplementation/consumption during pregnancy and cognitive benefits to 
infants and children 
Studies have shown that supplementation with n-3 LCPUFA during pregnancy and lactation 
resulted in increased cognition in the offspring. Supplementation with 1183 mg DHA and 803 
mg EPA per day during pregnancy and lactation increased children’s IQ at 4 years of age
51
. In 
another study women who consumed more than 340 g of fish per week during their 
pregnancy, their children had higher verbal IQ at age 8 compared to those children whose 
mothers consumed no fish during pregnancy
52
. 
In a longitudinal study design the maternal consumption of DHA during pregnancy was 
divided into low and high DHA intakes at the median intake point, and this study showed that 
women with high DHA intakes (approximately 181 mg/d) during pregnancy was associated 
with increased performance on an object search task in the offspring at 22 months of age, 
compared to the offspring from women with low DHA intakes (72 mg/d) during pregnancy
53
. 
This finding is consistent with previous findings. Furthermore, DHA supplementation 
prevented the reduction in sustained attention at 4, 6 and 9 months of age
31
. Collectively, 
these studies have shown that maternal consumption of higher levels of DHA during 
pregnancy results in increased cognition in the offspring. 
 
3.3.2 DHA supplementation to infants and children and cognitive benefits 
Supplementation trials in infants showed improved cognition in the infants. The DIAMOND 
trial was a 12 month intervention trial commencing in infants aged 1-9 days. These infants 
were randomised to one of 4 supplemental groups: 0.32% DHA and 0.64% AA; 0.64% DHA 
and 0.64% AA; 0.96% DHA and 0.64% AA; compared to the control group 0% DHA and 0% 
AA (i.e. the design was to vary the dose of DHA whilst maintaining AA dose). Combining 
the 3 DHA dose groups together and comparing to the control group, there was a significant 
increase in the Mental Development Index (MDI) (p=0.02), no significant improvement in 
cognition (p=0.08), and a significant improvement in language (p=0.01). There was also a 
negative correlation between infant red blood cell LA levels and cognition (rs=-0.19 p=0.039) 
and language (rs=-0.21 p=0.022) at 4 months of age, and the negative correlation with 
language persisted until 12 months of age (rs=-0.19 p=0.041), suggesting that higher LA 
levels in detrimental to cognition and language in infants
54
. Data from the DIAMOND trial 
shows that a balance between DHA and AA is required for optimal neurodevelopmental 
outcomes
55
  with a 1:1 or 1:2 balance of DHA to ARA being optimal and is consistent with 
the conclusions from a recent review
56
. In the RUTF as well as F75/100 and Modisco that are 
being used to date, the fatty acids composition is limit, based on our nutritional calculation 
using the fatty acids coumpound of Indonesian foods as Table 2 and 3. The most fatty acids 
compound is linoleic acid. Hence it is timely to consider adding DHA and AA into the 
formula at a ratio of 1:1 or 1:2.  
An increase in consumption of food sources containing n-3 LCPUFA e.g. fish, 
seafood
57,58 
and foods enriched with n-3
59,60
 has been found to be associated with an 
improvement of cognitive performance in school children. A randomized placebo-controlled, 
double-blind study showed a significant positive association (r
2
=0.14, p=0.018) between 
blood levels of DHA and higher scores on the Peabody Picture Vocabulary Test (PPVT) in 
healthy preschool children
61
. A six month randomly assigned experimental and control group 
intervention study has reported that consumption of bread spread with fish-flour suppling 892 
mg DHA per week, equivalent to 125 mg or 2 portions of medium fat fish per week 
significantly increased EPA and DHA, which had a positive impact on verbal learning and 
memory of African children (age 7-9 y)
62
.  
Similar findings have been reported in an intervention study of Indonesian and 
Australian primary school children who received supplementation with multiple 
micronutrients, as well as EPA plus DHA
63
. Improvement of biochemical markers (e.g. 
anaemia) has also been reported in a double blind-randomized controlled trial study in 
primary school Indian children after supplementation with multiple micronutrients and 
DHA
64
. However, in these two studies, there were no differences seen between the DHA 
group and placebo. The likely reason for no effect of DHA was that very small doses were 
used, namely 100mg DHA per day
64 
and 88mg DHA per day
64
.  
More recently, in the Dolab study where higher doses of DHA were used, DHA 
supplementation (600mg per day for 16 weeks) has shown improvements in the reading 
ability in school children aged 7-9 years whose initial reading ability was <20
th
 centile and 






These studies provide evidence that DHA supplementation or the consumption of 
marine-enriched food not only supported optimal health in school-aged children but also 
showed improvements in their academic achievement
61,62
. 
Sufficient intake of n-3 LCPUFA is crucial for supporting normal brain, cognitive and 
retina development, and protection against neuro-psychiatric disorders. Moreover, the brain 
keeps producing neurons, even into adulthood
66
. Research in primates and rodents has found 
that the brain cortex undergoes highly active synaptic turnover throughout life
67
. This 
suggests that sufficient intake of n-3 LCPUFA is fundamental, not only during the growth 
spurt period, but also across the life span. 
A number of hypotheses have been proposed to explain the poor learning of individuals 
with n-3 PUFA deficiency. The n-3 PUFA deficiency results in a significantly decreased 
number of neurons in the hippocampus, hypothalamus and cortex, brain areas that mediate 




, glucose transport capacity and 
glucose utilization in the brain
70
, cyclic adenosine monophosphate (cAMP) level in the 
hippocampus
71
 and capacity of phospholipid synthesis in the brain and hypothalamus
72,73
. The 
cAMP is a second messenger that is important in many biological processes. Any changes in 
the levels of catecholamines, glucose, cAMP and phospholipids can pose learning deficits.  
 
3.3.3 DHA supplementation and children and adolescent’s behaviour 
An Australian cross sectional study in 7-12 year olds with ADHD with and without learning 
difficulties showed that higher n-6 PUFA predicted poorer word reading, spelling, vocabulary 
and the lower ability to switch and control attention, whilst n-3 PUFA predicted lower anxiety 
and shyness
74
. Given the current much higher Australian intakes of n-6 PUFA (6-10 g of LA 
per day for 2-18 year olds) compared to total n-3 PUFA (1.0-1.6 g per day) which is at least 6 
times higher n-6 to n-3 intakes
37
, this is of concern. Furthermore, the n-3 LCPUFA intakes 
were much lower ranging from 0.13-0.21 g per day
37
. However, cross sectional studies do not 
show cause and effect. 
In an intervention trial in the UK, the Dolab study showed that DHA supplementation 
(600 mg per day for 16 weeks) resulted in improvements in hyperactivity and oppositional 
behaviour, global scales tapping emotional lability (mood swings) and restless impulsive 
behaviour as well as total ADHD-type symptoms
65
 compared to the control group. Another 
intervention trial also showed benefit of 732 mg n-3 LCPUFA supplementation per day and 
reductions in ADHD symptoms including inattention, hyperactivity and impulsivity
75
.  
In a review on n-3 deficits and adverse neurodevelopment and childhood behaviours
76
, 
the authors claim that a Western diet contains an imbalance of n-6 and n-3 PUFA which needs 
to be corrected. Given the low conversion rate of ALA to DHA and hence the essentiality of 
DHA
28
, DHA intakes should be increased for optimal neurological development and optimal 
health. 
 
3.4 n-3 LCPUFA intakes and recommended intakes 
Table 1 showed dietary n-3 LCPUFA intakes of children in many developed and developing 
countries are reported to be much lower than recommended desirable intakes (Table 2) with 
an exception is in Japan
77
.Intakes of n-3 LCPUFA (EPA plus DHA) in children that did not 
consume fish was at least twice as high as in those that did consume fish
78
. Fish consumption, 
even if low, is a major contributor to total n-3 LCPUFA intake. A study in Belgium has 
reported that fish and seafood were the highest contributors to EPA, DPA and DHA intake 
(53.5, 42.8 and 48.1%, respectively); however, only 31% of children in this study consumed 
fish. The mean of fish was 8.6 g/d in total children, and it was approximately 3-fold higher 
(27.4 g/d) in the seafood consumer
79
. It can be concluded that low fish consumption is the 




Table 1. Mean intake of EPA, DPA and DHA of different population studies of children 
Country Reference Number of children 
and age 




EPA DPA DHA Total n-3 LCPUFA 
     g/d mg/d % of E mg/d % of E mg/d % of E mg/d % of E 
Australia 80Meyer et al. 
2003 
383 (2-3 y)  
799 (4-7 y)  
739 (8-11 y)  
653 (12-15 y)  
433 (16-18 y)  
24h recalls  
 















































US 81Ervin et al., 
2004 
962 (6-11 y) 2208 
(12-19 y) 


















Australia 82Howe et al. 
2006 
1921 (2-11 y)  
1086 (12-18 y)  
24h recalls  
 








































Belgium 79Sioen et al. 
2007 
661 (2.5-6.5 y) Parentally reported 3d 
EDR  
Sum of LNA, EPA, 




















Hellert et al.  
2009 
1024  (2-18 y) 3d weighed records 
(yearly) 




















Guatemalan 84Bermudez et 
al., 2010 
219 (8-12 y, LSES) 
230 (8-12 y, HSES) 














32 (2) §† 






EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; n-3 LCPUFA, omega-3 long chain polyunsaturated fatty acid; LNA, linolenic acid; 
LSES, Low social economy status; HSES, high social economy status; n/a, not available; *, mg/d/energy (MJ); §,Mean ± standard deviation; §§, Mean (inter quartile range); 
§†, Mean ± SEM; ∞, Mean ± median;††, The lower and the higher mean of all age groups; ‡ Seafood 
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3.4.1 Infant and children n-3 LCPUFA intakes 
DHA intake in children aged 24-35 months (n=221) and 36-48 months (n=236) from 
rural Bangladesh was 30 mg and 20 mg respectively
85
. Total marine intakes (i.e. EPA 
and DHA intakes) were 150 mg per day in 404 children aged 1-11 years from Denver 
Colorado in the USA
86
. The total mean n-3 LCPUFA (EPA, DPA and DHA) intake in 
Australia was approximately 150 mg per day in 2-12 years olds
37
. These infants and 
children’s intakes are below those recommended intakes as shown in Table 2.  
The n-3 LCPUFA are involved in various neuronal processes, ranging from 
regulation of gene transcription to effects on cellular signalling processes
9
, and 
protection against the pathogenesis of retinal diseases
33
. Nutrient deficiency during the 
brain growth spurt, which is between the last trimester of gestational and the first two 




Table 2. Recommended Intakes for babies, infants, children and adolescents per day 
(unless otherwise stated) for EPA and/or DHA 
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For age range 7mths to 2 years;  
^
For age range 2 yrs to 9 yrs;  * For age range 0-5mths;  

For age range 6-11 mths;  

For age range 12-23 mths;  G is girls; B is boys 
 
3.4.2 Pregnant women DHA intakes 
Table 3 shows recommended desirable intakes of dietary n-3 LCPUFA for pregnant and 
lactating women. The vast majority of Australian women of child bearing age are not 
meeting the recommended DHA intake of 200 mg per day and only the 90
th
 centile of 
DHA intakes meets the recommended intake of 200 mg DHA per day
91
. Even 
Australian pregnant women are only averaging 99 mg DHA per day and the median 
DHA intake is 75 mg per day
92
  which is less than half the recommended DHA intake. 
Other countries also do not meet the recommended 200 mg DHA intakes per day, such 
as the USA 110 mg DHA mid pregnancy and 80 mg DHA one month prior to 
delivery
93
, USA 77 mg DHA per day
94
, China 10 mg DHA per day
95
, UK 80-90 mg 
DHA per day
53
. Countries that have a high intake of fish/seafood do meet the 
recommended intake of 200 mg DHA per day such as Japan 227-238 mg DHA per 
day
96
 and Korea 300 mg DHA per day
97
, highlighting the importance of regular 
fish/seafood consumption to meet the recommended intake of 200 mg DHA per day.  
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To meet the recommended 200 mg DHA per day intakes a pamphlet and shopping 
card was developed for pregnant women and showed that it was useful, desired by 
pregnant women and also resulted in increased DHA intake
98
. The pregnant women 
found that the pamphlet expanded their knowledge about the benefits of DHA, food 





Table 3.  Recommended DHA Intakes per day for pregnant and lactating women 
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The PeriLip and EARNEST 
projects of the European 
Commission
103
  (expert scientific 
organisation) 
 
100-200mg DHA in addition to 
normal adult recommendation  











500mg EPA and DHA 
Germany 
German Society for Nutrition
101
   






Swiss Society for Nutrition 
Research / Swiss Nutrition 
Association
101
                   (expert 
scientific organisation) 
>200mg DHA 
United States of America 
March of Dimes
104
                         
(expert scientific organisation) 
 
200mg DHA 
Overall >200mg DHA 
 
 
3.4.3 Global n-3 LCPUFA intakes 
Micha and colleagues reported the global, regional and national consumption levels of 
various fats including the seafood n-3 LCPUFA from 266 country specific nutrition 
surveys
105
. The n-3 LCPUFA intakes ranged from 5 to 3,886 mg per day with an overall 
average of 163 mg per day. Only 18.9% of the estimated world’s population met the 
recommended intake of 250 mg per day of EPA and DHA
105
. Given the evidence above, 
we need to consider adding n-3 LCPUFA in the diet or formula to promote optimal 
growth and development of malnutrition including stunting children.  
 
3.5 Breastmilk composition 
The quality of fatty acids in breastmilk has changed considerably over the past 30-40 
years
106
; where LA has doubled (from 7% to 14% of total fatty acids) and DHA has 
halved (from 0.4% to 0.2% of total fatty acids). This dramatic change in breastmilk fatty 
acid composition is likely to be reflective of our dietary intakes of these fatty acids over 
this period of time. Given the benefits of DHA on mental development index and 
language
52
, this decrease in DHA in breastmilk is of great concern. Furthermore, given 
that high LA levels in infants correlates negatively with language and cognition, this 




3.6 The role of n-3 LCPUFA in chronic-diseases prevention 
The progression of risk factors for chronic diseases such as cardiovascular diseases 
(CVD) that are associated with age can be either delayed or accelerated as a function of 
lifestyle choice
107
. Dietary habits in childhood influence the development of an 
individual's CVD risk profile in later life
108
, whilst, early intake of n-3 LCPUFA has 
shown beneficial effects regarding the prevention of CVD in later life
57,58
. Several 
randomized double-blind studies in children aged between 2-18 years have 
demonstrated beneficial outcomes for a lower risk of development of chronic diseases
57, 
106,107,108,109,110
and a better CVD risk factor profiles in children following n-3 LCPUFA 
supplementation
111-113
. Low concentrations of DHA have been found to be associated 
with increased concentrations of C-reactive protein (CRP), a sensitive predictor of CVD 
risk
114
, in overweight teenagers
115
. Conversely, an increased intake of n-3 LCPUFA has 
been shown to modulate vascular functions and inflammatory markers, including 
lymphocytes, monocytes and level of TNF-α, interleukin (IL)-1β and IL-6, in obese 
adolescents
107
. A low n-3 index, the sum of erythrocyte EPA and DHA, expressed as a 
percentage (weight/weight) of total fatty acid concentrations in red blood cell 
membranes (but not in plasma)
116
,has also been found in obese school age children and 
is associated with insulin resistance
117
. The n-3 index is considered as a potential 
biomarker that can identify persons at risk for coronary heart disease in adults
118,119
. A 
value of less than 4% is categorized as high risk while >8% is categorized as low 
risk
120118
. It has been reported that higher intake of EPA and DHA through fish 
consumption is associated with higher n-3 index in healthy adolescents and reduced 
CVD factors in boys
121
. 
Decrease in DHA levels was associated with increased stearoyl-CoA desaturase 
(SCD), a desaturating enzyme that modulates fatty acid composition and might 
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contribute to development of metabolic syndrome in obese children
122
. A reduction in 
biomarkers of CVD risk namely E-selectin and inter-cellular adhesion molecules 
(ICAM)-1 has also been observed in healthy children aged 8-14 years following n-3 
LCPUFA supplementation
123
. E-selectin and ICAM-1 are members of cell adhesion 
molecules that are involved in the inflammatory development to endothelial damage, 
such as seen in CVD
124,125
. Additionally, improvement in endothelium-dependent flow-
mediated dilation (FMD) of the brachial artery after DHA supplementation (1.2 g/d for 
6 weeks) has also been reported in hyperlipidemic children at risk for early heart 
disease
126
. Supplementation of 900 mg/d n-3 LCPUFA for a month has been reported to 
have synergistically reduced insulin resistance together with weight loss in obese at-risk 
children. The mechanistic effect may be through an increased production of adiponectin 
and a decrease in inflammatory biomarkers such as TNF- α
127
. 
An intervention study in healthy children (8-14 y) has reported that consumption 
of 600 mL/d milk enriched with fish oil, oleic acid, minerals and vitamins (Puleva Max 
containing fish oil, EPA=10 mg/100 mL and DHA=20 mg/100 mL, n-3=35 mg/100 mL; 
oleic acid; carbohydrates (sugar and honey); vitamins: A as retinyl ester, B1, B2, B3, 
pantothenic acid, B6, biotin, folic acid, B12, C, D, and E; minerals: calcium, 
phosphorus, zinc) that was  low in saturated fatty acids reduced incidence of endothelial 
cell activation, a CVD risk biomarker
128
.  
Therefore it can be suggested that sufficient intake of n-3 LCPUFA during 
childhood and adolescence is not only necessary for supporting normal cognitive 
development during childhood but also appears to reduce risk factor for cardiovascular 
disease, a disease that progresses throughout life. 
 
4. Foods enriched with n-3 LCPUFA  
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In countries with traditionally low fish consumption as well as for certain individuals or 
communities who may not be suitable or convenient to eat fish, n-3 enriched foods 
could play an important role in meeting the recommendations for n-3 LCPUFA. 
Ovolacto vegetarian may obtain a limited amount of n-3 LCPUFA from eggs, milk and 
dairy products, while vegan must rely on in vivo biosynthesis of these fatty acids from 
ALA which it depend on the ratio of ALA and LA from the diet
129
. An international 
recommendation of consumer’s need of a daily 500 mg of n-3 LCPUFA for each person 
have been calculated and showed that current global fish harvest will not supply this 
recommendation
130
. Therefore alternative sources are required to meet the 
recommendation for n-3 LCPUFA for optimal health.  
One method to increase n-3 LCPUFA is to incorporate the main sources of n-3 
LCPUFA into regularly consumed foods. These include enrichment foods with fish oils, 
single cell micro algal oils and/or biomass, and under-utilized marine sources e.g. 
krill
131
. A number of n-3 enriched foods with the alternative source of n-3 and fish oil 
e.g. breads, eggs, milk and yoghurt can be found in marketplace in Australia and in 
many countries such as Europe, Canada and South America
25
. 
It has been reported that regular consumption of a variety of n-3 fortified foods (8 
meals/day) providing 50 and 150 mg EPA plus DHA per serving increases the daily n-3 
LCPUFA intake of Australian adults from 100-200 mg/d to 1000 mg/d
132
, double the 
recommended n-3 LCPUFA intakes. Furthermore, an increase in n-3 LCPUFA 
concentration in erythrocytes by 35 and 53% at 3 and 6 months respectively, after 
supplementation, which is equivalent to an n-3 index of increased from 4 to 7% over 6 
months study, placing these subjects in lower risk for cardiac death
133
.These 
incensements have also been reported to be associated with CVD risks reduction and 
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positively associated with arterial compliance assessment and negatively associated 
with serum CRP and urinary 11-dehydro-TXB2 excretion
133
.  
Food matrix or carrier food can influence bioavailability and possible 
physiological effects of n-3 LCPUFA in the systemic circulation or the target organ
134
. 
A mini review of currently available published studies on the influence of consumption 
of products enriched with n-3 LCPUFA
135
 demonstrated a comparable bioavailability 
between foods enriched with n-3 and fish oil supplements. The bioavailability and 
health effects of food products that are potentially enriched with n-3 LCPUFA are 
presented in the following part. 
  
 
4.1 Bread enriched with n-3  
Bread is a staple for large numbers of people, especially in Western countries such as in 
Australia. Enrichment of bread with n-3 LCPUFA may have a critically important role 
because the typical Western diet, which is relatively high in n-6 and low in n-3
8
. Bread 
is an ideal medium for n-3 because the CO2 produced during dough fermentation 
protects the oil from oxidation, especially while it is exposed to high temperatures 
during baking
136




Liu et al. (2001)
138
 reported an increase in plasma levels of EPA, DHA and total 
n-3 FA has been reported of hyperlipidaemia subjects after 2 and 4 weeks by consuming 
93 g bread per day containing 1.3 g stable fish oil. Furthermore, the authors also 
reported a decrease in triglycerides and malondialdehyde (MDA), one of several 
potential marker of oxidative stress or lipid peroxidation
139,140






Microencapsulated fish oil incorporated into bread and also biscuits and soup 
(providing 0.9 g n-3 PUFA intake per day) was equally effective to that from fish oil 
capsules (three 1-g capsules per day) in increasing platelet EPA and DHA of healthy 
females, after 4 weeks intervention
137
. Consumption of a low dose of n-3 LCPUFA 
supplemented in bread (20 mg of n-3 LCPUFA per slice, derived from 
microencapsulated tuna oil on average 6 to 8 slices per day for 3 weeks significantly 
increased concentration of total n-3LCPUFA (EPA, DPA, DHA) from 2.0 to 2.4% in 
total plasma and from 3.9 to 4.3% in PL fraction
141
. 
Microencapsulation of fish oil into food products such as bread has advantages 
including: 1) microencapsulation can convert fish oils to powder form, thereby 
increasing the number and type of food into which it can be incorporated; 2) 
microencapsulation, in minimising oxidation mainly by avoiding contact between the 
fish oil and oxygen in the air, has the potential to extend the shelf-life of fish oil and 
also to improve the palatability of fish oil-enriched food products. The palatability of 
bread was reported to be good and appearing to be the best vehicle for increasing daily 




4.2 Eggs enriched with n-3 LCPUFA 
Eggs can be enriched with n-3 LCPUFA by the addition of fish meal or seed oils (flax 
or rapeseed) to animal feeds, and this also increasing the n-3 PUFA in chicken 
meat
142,143
. Chicken are able to convert ALA to DHA better than human
144
.  
The food enriched with n-3 consumption demonstrates some positively affects in 
the plasma lipid profile in humans. Consumption of two eggs enriched with n-3 PUFA 
for 18 days in healthy volunteers significantly increased in HDL-C and decreased in 





study in normolipidemic volunteers eating four n-3 PUFA eggs (from flaxseed-fed 
hens) per day for 2 weeks showed that no significant changes were observed in 
concentration of total cholesterol, HDL-cholesterol, or plasma triglyceride, and a 
significant increase in DHA (33%) and total n-3 PUFA and significant decrease in ratio 
n-6 to n-3 FA in the blood platelet phospholipids
146
. Two weeks consumption of one 
egg enriched with n-3 per day (from hens fed containing 10% flaxseed) did not 
significantly increase concentration of plasma total LDL and LDL cholesterol and 
triglyceride compared with regular egg, and there was a trend of slightly lower 
concentration of LDL cholesterol
147
. A study in hypercholesterolemic subjects for 6 




A randomized double-blind, cross-over study of hypercholesterolemic patients has 
reported that eating two eggs enriched with n-3 from hens fed flaxseed providing 217 
mg of DHA and 629 mg total n-3 LCPUFA per day, significantly increased in EPA plus 
DHA levels in serum phospholipid by 23%, and significance correlated to a reduction of 
fatal ischemic heart diseases risk and did not change levels of lipid and total serum 
cholesterol
149
. A double-blind, cross-over study in healthy individual with an age over 
45 years concluded that consumption of one egg enriched with n-3 (from hens fed 
rapeseed oil, and the amount of ALA, EPA and DHA are 9.3, 0.2 and 1.5% in one egg 
respectively) increased ApoA1 and decreased ApoB/ApoA1 ratio, and had no negative 
impact on blood lipids and inflammatory markers
150
. Apo-A1 is a major component of 
HDL that is responsible for carrying cholesterol from arteries, whilst Apo-B is 
responsible for carrying cholesterol to tissues, and they are accepted as superior markers 
of CVD risk
151
. It has also been reported that a high Apo-B/Apo-A1 ratio was 





An increase in serum lutein, an antioxidant that protects the macula from light-
initiated oxidative damage
153
 has been found in healthy adults
154
 and in healthy lacto-
ovo-vegetarian (LOV) adults
155
 following intervention by consumption of n-3 enriched 
eggs. Lutein is highly concentrated in the human eye, in the macula, retina fluid, rod 
outer segment membranes and the lens of the eye. Together with DHA, lutein can be 




4.3 Milk enriched with n-3 LCPUFA 
Milk is a very efficient carrier for fat absorption, due to high dispersion of fat milk in 
micelles facilitating in a large surface for absorption
157
. Bioavailability of 
microencapsulated fish oil incorporated into milkshake
158
 has been shown similar to that 
from fish oil capsules after 4-week intervention. Semi-skimmed milk containing n-3 
fatty acids from fish oil supplying 0.3 g of DHA plus EPA per day increase in plasma 
concentrations of DHA plus EPA (30% on average) together with a significant 19% 
reduction in fasting plasma triacylglycerols levels after 6 weeks intervention
157
. 
Consumption of 500 mL of the n-3 enriched milk providing DHA and EPA 0.13 g and 
0.2 g respectively significantly increased plasma levels of DHA and EPA (on average 
30%) and decreased in plasma levels of homocysteine (13%), after 2 months 
intervention
159
. In another study, an average inclusion of 300 mg EPA plus DHA in 
milks produced a 25-50% improvement in plasma levels of fatty acids after a minimum 
period of 6 weeks
113
.  
Blood lipid effects of the n-3 enriched milks have been reported in healthy 
children and adults, and also in CVD patients
143
. All the studies concluded that 
consumption of milk substituted with EPA plus DHA, PUFA and oleic acid for more 
than 6 weeks resulted in sustainable reductions blood lipid concentration including total 
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cholesterol (range 4-11%) and LDL-cholesterol (6-20%), particularly when baseline 
values before intervention were increased
143
. Another study by Romeo et al.
123 
reported 
that consumption of milk enriched with fish oil EPA plus DHA for 5 months 
significantly decreased endothelial cell activation indices namely ICAM-1 in healthy 
children aged 8-14 y. Soluble ICAM-1 is associated with future risk factors for 
atherosclerosis in children
160
, while high concentration of serum E-selectin is correlated 
with the development of atherosclerosis and increase in CVD risk in adults
161
. This 
suggests that consumption of food enriched with n-3 may reduce CVD risks.  
Other study reported that cconsumption of 200 mL milk fortified with 2 g fish oil 
twice a week for six months (provided 200 mg EPA plus 1 g DHA each day) 
significantly increased n-3 LCPUFA in plasma phosphatidylcholine and decreased 
episode and duration of illness, particularly upper respiratory tract infection such as 




4.4 Yoghurt enriched with n-3 LCPUFA 
Yoghurt enriched with n-3 LCPUFA is possibly a better way to deliver compared to 
milk. Compared to milk enriched with fish-oil, yoghurt enriched with fish-oil 
demonstrated less susceptibility to oxidation
163
, thereby reducing fishy odours and 
flavour
164
. Antioxidant peptides released during the fermentation of milk by lactic acid 
bacteria and/or the lower oxygen content of yoghurt might responsible to the higher 
oxidative stability of yoghurt
165
. Technique in adding fish oil for example net fish oil 






A bioavailability study in humans demonstrated that yoghurt drink was the best 
matrix compared to fitness bar, butter and bread containing fish oil for providing fast 
absorption of EPA and DHA
166
 which might be due to the preformed emulsions. 
 
4.5 Other foods enriched with n-3 LCPUFA 
A number of food products such as dip and juice have also been enriched with n-3 
LCPUA and showed positive effect to lipid profile. Consumption n-3 PUFA-enriched 
dip 100 g/d supplying 1.3-1.4 g of n-3 PUFA(sum of ALA, EPA, DPA and DHA) for 6 
weeks increased EPA, DPA and DHA concentrations in plasma lipids by 117, 15 and 
80% respectively, significantly reduced plasma triglyceride level (1.93 mmol/L to 1.27 
mmol/L) and increased HDL-cholesterol in people with type 2 diabetes mellitus
167
. A 
study in healthy children age 4-12 y in US reported an increase in phospholipids DHA 
contents by 40-50 and 65-70% after 6 weeks supplementation of 180 mL juice/d 
fortified with 50 and 100 mg/d microencapsulated-algal DHA respectively
62
. Algal oil 
provide an equivalent amount of DHA to bloodstream as cooked salmon, whereas 
bioavailability of 600 mg/d DHA from salmon or algal oil are equivalent for 




5. Inclusion of n-3 LCPUFA in RUTF rationale 
In this review, we have reviewed the evidence that humans are able to synthesise the n-3 
LCPUFA from ALA, albeit limited, especially to DHA. Therefore, rather than relying 
on the conversion of ALA to n-3 LCPUFA including DHA, it is better to consume 
preformed n-3 LCPUFA. We have provided evidence that n-3 LCPUFA are vital 1) for 
neurological development, especially DHA; 2) from birth to old age, especially DHA; 
3) for cognitive development, especially DHA; and 4) to prevent chronic disease in 
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children. However, our current n-3 LCPUFA intakes globally are not meeting the global 
recommended intakes. We are consuming too much LA and not enough n-3 LCPUFA 
and this is reflective in current breastmilk composition. The majority of this evidence 
reported in this review has been conducted in children that are not considered stunted, 
as there is a lack of research in this specific population. There are two studies that have 
shown beneficial effects of LCPUFA substitution for children with malnutrition
17,18
  but 
more research is warranted in those suffering stunting.  Given that 1) DHA consumption 
during pregnancy results in increase cognition in the offspring; 2) DHA is better than 
LA in terms of growth (i.e. increased height but not weight or fatness), whereas LA 
increases adiposity but not height; 3) higher LA intake in the first 12 months of life 
results in reduced cognition and reduced language in infants and 4) DHA 
supplementation in children results in increased cognition: it is timely that we consider 
adding n-3 LCPUFA, especially DHA to RUTF. Furthermore, to ensure optimal benefit 
we recommend replacing LA in RUTF with DHA and AA in a ratio of 1:1 or 1:2 
(DHA:AA ratio). More research is warranted on RUTF containing DHA and AA with 
little or no LA in preventing stunting. 
 
6. Conclusions 
The n-3 LCPUFA must be obtained from pre-formed n-3 LCPUFA (not from the 
conversion from ALA to DHA) which are provided in fish.  However, numerous 
barriers to consume fish lead to a failure to meet the reference values for fish 
consumption. A low dose of enrichment food with n-3 LCPUFA can be used as a long-
term strategy to achieve the health benefits of n-3 LCPUFA for optimal health, 
including for stunted children. Due to the remedial formula to treat stunted children 
currently lacking on n-3 LCPUFA with the primary fatty acids compound being LA, it 
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is timely to consider adding DHA and AA into the formula at a ratio of 1:1 or 1:2. Food 
enrichment with specific nutrients such as n-3 enriched food can lead to relatively rapid 
changes in the specific nutritional status of a community, and is a cost-effective public 
health intervention. However the items need to be consumed in adequate amount by a 
large proportion of target individuals in the population and the levels of fortification 
must be high enough to substantially increase the intakes. 
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